文章：

通过肿瘤微环境的免疫调节改善头颈癌治疗

Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment

原文发布日期：2022-12-01

DOI: 10.1038/s41568-022-00531-9

类型: Review Article

开放获取: 否

英文摘要：

Targeted immunotherapy has improved patient survival in head and neck squamous cell carcinoma (HNSCC), but less than 20% of patients produce a durable response to these treatments. Thus, new immunotherapies that consider all key players of the complex HNSCC tumour microenvironment (TME) are necessary to further enhance tumour-specific T cell responses in patients. HNSCC is an ideal tumour type in which to evaluate immune and non-immune cell differences because of two distinct TME aetiologies (human papillomavirus (HPV)-positive and HPV-negative disease), multiple anatomic sites for tumour growth, and clear distinctions between patients with locally advanced disease and those with recurrent and/or metastatic disease. Recent technological and scientific advancements have provided a more complete picture of all cellular constituents within this complex TME and have evaluated the interplay of both immune and non-immune cells within HNSCC. Here, we include a comprehensive analysis of the complete ecosystem of the HNSCC TME, performed utilizing data-rich resources such as The Cancer Genome Atlas, and cutting-edge techniques, such as single-cell RNA sequencing, high-dimensional flow cytometry and spatial multispectral imaging, to generate improved treatment strategies for this diverse disease.

摘要翻译： 

靶向免疫疗法提高了头颈鳞状细胞癌（HNSCC）患者的生存率，但仅有不到20%的患者对这些治疗产生持久反应。因此，需要开发新型免疫疗法，综合考虑复杂HNSCC肿瘤微环境（TME）中的所有关键因素，以进一步增强患者的肿瘤特异性T细胞反应。HNSCC是评估免疫细胞与非免疫细胞差异的理想肿瘤类型，因其具有两种不同的TME病因（人乳头瘤病毒阳性与阴性病变）、多个肿瘤生长的解剖部位，以及局部晚期患者与复发/转移患者之间的明显区别。近期技术和科学进展为这一复杂TME内的所有细胞组分提供了更完整的图谱，并评估了HNSCC中免疫细胞与非免疫细胞的相互作用。本文通过对HNSCC TME完整生态系统进行全面分析，利用癌症基因组图谱等数据资源，以及单细胞RNA测序、高维流式细胞术和空间多光谱成像等前沿技术，为这种异质性疾病制定更优化的治疗策略。

原文链接：

Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment